64188-97-2

Basic information

• Product Name: 3-AMINO-4-PYRIDINECARBOXAMIDE
• Synonyms: 3-AMINOISONICOTINAMIDE;3-AMINO-4-PYRIDINECARBOXAMIDE;4-Pyridinecarboxamide,3-amino-(9CI);methyl 3-aminoisonicotinate (en);3-aMino-4-carbaMoylpyridine
• CAS NO: 64188-97-2
• Molecular Formula: C₆H₇N₃O
• Molecular Weight: 137.14
• Product Categories: AMIDE;Pyridines;Pyridine
• Mol File: 64188-97-2.mol

Chemical Properties

• Melting Point: 84-86°
• Boiling Point: 369.225 ºC at 760 mmHg
• Flash Point: 177.101 ºC
• Appearance: /
• Density: 1.323 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.644
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.73±0.50(Predicted)
• CAS DataBase Reference: 3-AMINO-4-PYRIDINECARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-4-PYRIDINECARBOXAMIDE(64188-97-2)
• EPA Substance Registry System: 3-AMINO-4-PYRIDINECARBOXAMIDE(64188-97-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 64188-97-2(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
3-Amino-4-pyridinecarboxamide is used as an anticancer agent for its ability to inhibit enzymes that play a crucial role in nucleotide biosynthesis and DNA repair. This action can disrupt the proliferation and survival of cancer cells, making it a potential therapeutic option for various types of cancer.
Used in Diabetes Management:
In the field of diabetes, 3-Amino-4-pyridinecarboxamide is used to enhance insulin sensitivity, which can help in managing blood sugar levels more effectively. Additionally, its protective effects on pancreatic beta cells could contribute to the maintenance of insulin production, offering a dual approach to diabetes treatment.
Used in Pharmaceutical Research:
3-Amino-4-pyridinecarboxamide serves as a valuable compound in pharmaceutical research for the development of new drugs targeting cancer and diabetes. Its unique mechanism of action provides a foundation for designing novel therapeutic agents that can potentially improve patient outcomes in these disease areas.
Used in Drug Development:
In drug development, 3-Amino-4-pyridinecarboxamide is utilized as a lead compound for the creation of new pharmaceuticals. Its potential to modulate key biological pathways involved in disease processes makes it an attractive candidate for further optimization and development into effective treatments.

InChI:InChI=1/C6H7N3O/c7-5-3-9-2-1-4(5)6(8)10/h1-3H,7H2,(H2,8,10)

Upstream product

• 55279-30-6 methyl 3-aminoisonicotinate 
• 59290-91-4 3-nitroisonicotinamide 
• 7579-20-6 3-Aminopyridine-4-carboxylic acid 
• 78790-79-1 3-amino-4-cyano-pyridine 
• 55-22-1 pyridine-4-carboxylic acid 
• 1453-82-3 isonicotinamide 

Downstream Products

• 342899-34-7 3-amino-2-chloropyridine-4-carboxamide 
• 144288-49-3 3-amino-4-(aminomethyl)pyridine 
• 51752-67-1 4-chloro-pyrido[3,4-d]pyrimidine 
• 19178-25-7 pyrido-<3,4-d>pyrimidin-4(3H)-one 
• 1589562-14-0 (R)-3-{2-[2-(4-ethoxycarbonylmethoxyphenylamino)pyridin-4-yl]pyrido[3,4-d]pyrimidin-4-ylamino}pyrrolidine-1-carboxylic acid tert-butyl ester 
• 908240-50-6 2,4-dichloropyrido[3,4-d]pyrimidine 
• 21038-67-5 pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Synthesis of 2-aryl quinazolinones: Via iron-catalyzed cross-dehydrogenative coupling (CDC) between N-H and C-H bonds

Herein, we describe the direct synthesis of quinazolinones via cross-dehydrogenative coupling between methyl arenes and anthranilamides. The C-H functionalization of the benzylic sp3 carbon is achieved by di-t-butyl peroxide under air, and the subsequent amination-aerobic oxidation process completes the annulation process. Iron catalyzed the whole reaction process and various kinds of functional groups were tolerated under the reaction conditions, providing 31 examples of 2-aryl quinazolinones using methyl arene derivatives in yields of 57-95percent. The synthetic potential has been demonstrated by the additional synthesis of aryl-containing heterocycles. This journal is

Substrate Profiling of the Cobalt Nitrile Hydratase from Rhodococcus rhodochrous ATCC BAA 870

The aromatic substrate profile of the cobalt nitrile hydratase from Rhodococcus rhodochrous ATCC BAA 870 was evaluated against a wide range of nitrile containing compounds (>60). To determine the substrate limits of this enzyme, compounds ranging in size from small (90 Da) to large (325 Da) were evaluated. Larger compounds included those with a biaryl axis, prepared by the Suzuki coupling reaction, Morita–Baylis–Hillman adducts, heteroatomlinked diarylpyridines prepared by Buchwald–Hartwig crosscoupling reactions and imidazo[1,2a]pyridines prepared by the Groebke–Blackburn–Bienaymé multicomponent reaction. The enzyme active site was moderately accommodating, accepting almost all of the small aromatic nitriles, the diarylpyridines and most of the biaryl compounds and Morita–Baylis–Hillman products but not the Groebke–Blackburn–Bienaymé products. Nitrile conversion was influenced by steric hindrance around the cyano group, the presence of electron donating groups (e.g., methoxy) on the aromatic ring, and the overall size of the compound.

Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors

Transient receptor potential melastatin 2 (TRPM2), a Ca2+-permeable cationic channel, plays critical roles in insulin release, cytokine production, body temperature regulation and cell death as a reactive oxygen species (ROS) and temperature sensor. However, few TRPM2 inhibitors have been reported, especially TRP-subtype selective inhibitors, which hampers the investigation and validation of TRPM2 as a drug target. To discover novel TRPM2 inhibitors, 3D similarity-based virtual screening method was employed, by which 2,3-dihydroquinazolin-4(1H)-one derivative H1 was identified as a TRPM2 inhibitor. A series of novel 2,3-dihydroquinazolin-4(1H)-one derivatives were subsequently synthesized and characterized. Their inhibitory activities against the TRPM2 channel were evaluated by calcium imaging and electrophysiology approaches. Some of the compounds exhibited significant inhibitory activity, especially D9 which showed an IC50 of 3.7 μM against TRPM2 and did not affect the TRPM8 channel. The summarized structure-activity relationship (SAR) provides valuable insights for further development of specific TRPM2 targeted inhibitors.

Synthesis of Novel Hydroxymethyl-Substituted Fused Heterocycles

Examples of hydroxymethylated analogues of heteroaryl cores such as quinazolin-4-ones, isoquinolin-1(2H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, chromen-4-ones and pyrrolo[2,1-f][1,2,4]triazin-4(3H)-ones are sparse or non-existent in the scientific literature. We have demonstrated that such compounds are accessible by using standard procedures from readily available raw materials.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

2-Aminomethylphenylamine as a novel scaffold for factor Xa inhibitor

We have been researching orally active factor Xa inhibitor for a long time. We explored the new diamine linker using effective ligands to obtain a new attractive original scaffold 2-aminomethylphenylamine derivative. Compound 1D showed very strong in vitro and in vivo factor Xa inhibitory activity, as well as favorable PK profiles in po administration to monkeys.

SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY

The present invention relates to substituted ring fused azines and methods of using said compounds in treating cancers. More specifically, the present invention relates to the preparation of 4-alkyl-2-(heterocyclic)-azines and their use as cancer agents o

Preparation of 4-substituted 3-amino-2-chloropyridines, synthesis of a nevirapine analogue

A new method for preparing 3-amino-2-chloropyridines with a substituent (methyl, phenyl, carboxamide, methoxycarbonyl, acetyl, benzoyl and cyano) at the 4-position has been developed. An isoquinoline analogue of the reverse transcriptase inhibitor Nevirapine has been synthesized from the 4-amino-3-chloroisoquinoline.